As the leader of Juno's business development efforts, Christian Hordo directs the growth of the BD group, chairs the cross-functional committee which sets the company’s partnering strategy, and specializes in complex transactions with innovative structures. Juno has been one of the most prolific deal makers in the immuno-oncology space, consolidating best-in-class products and technologies around its cell therapy platform. Christian has served as the principal negotiator on multiple major licensing deals and acquisitions at Juno, most notably the broad strategic collaboration with Celgene, which brought in over $1 billion in capital.

Prior to joining Juno, Christian spent five years at Genentech in business development, executing numerous transactions, including the $150M upfront IDO license agreement with NewLink Genetics. While at Genentech, he also served as Project Team Leader, leading a cross-functional team to progress a novel therapeutic through IND-enabling studies.  

Christian earned his MBA from Harvard Business School, graduating with high distinction as a Baker Scholar. Prior to that, he performed his graduate research in Microbiology at the University of Toronto and completed his undergraduate degree in Psychology at McGill University. He has co-authored papers in PNAS and Developmental Biology. He also spent several years as an entrepreneur, founding and ultimately selling a successful online company.